Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

Verena Schlintl Florian Huemer Richard Greil Lukas Weiss

J Gastrointest Oncol

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology, and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, Salzburg, Austria.

Published: April 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107630	PMC
http://dx.doi.org/10.21037/jgo-20-230	DOI Listing

Publication Analysis

Top Keywords

ramucirumab folfiri

folfiri irinotecan

irinotecan second-line

second-line therapy

therapy advanced

advanced metastatic

metastatic gastric

gastric gastroesophageal

gastroesophageal junction

junction adenocarcinoma

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!